Cytokinetics Inc (CYTK.OQ)
CYTK.OQ on NASDAQ Stock Exchange Global Select Market
7.25USD
4:00pm EDT
7.25USD
4:00pm EDT
Change (% chg)
$0.15 (+2.11%)
$0.15 (+2.11%)
Prev Close
$7.10
$7.10
Open
$7.10
$7.10
Day's High
$7.35
$7.35
Day's Low
$7.10
$7.10
Volume
48,278
48,278
Avg. Vol
119,185
119,185
52-wk High
$17.20
$17.20
52-wk Low
$6.80
$6.80
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
| Name | Age | Since | Current Position |
|---|---|---|---|
Leonard Patrick Gage |
74 | 2010 | Independent Chairman of the Board |
Robert Blum |
53 | 2007 | President, Chief Executive Officer, Director |
Ching Jaw |
54 | 2017 | Chief Financial Officer, Senior Vice President |
Sharon Barbari |
62 | 2017 | Executive Vice President - Finance |
Fady Malik |
52 | 2015 | Executive Vice President - Research and Development |
- BRIEF-Cytokinetics Qtrly Net Loss Per Share $0.75
- BRIEF-Cytokinetics Announces Progress Against Vision 2020
- Cytokinetics sinks on abandoning ALS drug after failed trial
- UPDATE 4-Cytokinetics sinks on abandoning ALS drug after failed trial
- BRIEF-Cytokinetics Inc announces negative results from VITALITY-ALS